e-learning
resources
Vienna 2009
Monday, 14.09.2009
Pathobiology of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Copper restriction prevents and reverses angioproliferation in experimentally induced pulmonary arterial hypertension (PAH)
H. Bogaard, R. Natarajan, S. Mizuno, D. Kraskauskas, N. Voelkel (Richmond, United States Of America)
Source:
Annual Congress 2009 - Pathobiology of pulmonary hypertension
Session:
Pathobiology of pulmonary hypertension
Session type:
Oral Presentation
Number:
1588
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Bogaard, R. Natarajan, S. Mizuno, D. Kraskauskas, N. Voelkel (Richmond, United States Of America). Copper restriction prevents and reverses angioproliferation in experimentally induced pulmonary arterial hypertension (PAH). Eur Respir J 2009; 34: Suppl. 53, 1588
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH).
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects
Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016
Year: 2017
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target
Source: Eur Respir J 2011; 38: 1453-1460
Year: 2011
R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models
Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020
Year: 2021
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Endothelial cell mechanics are altered in pulmonary arterial hypertension (PAH)
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension
Source: Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept